OSE Immunotherapeutics announced its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. Read more...
Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital (RWJ) announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. Read more...
VitalConnect® announced it was granted Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) as part of the response to the COVID-19 pandemic. Read more...